OrbiMed Advisors AVBP Position
Active3-Fund ConvergenceOrbiMed Advisors held their position in ArriVent BioPharma, Inc. (AVBP) in Q4 2025, holding $60.9M worth of shares across 3,027,328 shares.
The position was first reported in Q1 2024 and has been tracked across 8 quarterly 13F filings.
AVBP is a convergence signal: 3 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 3 readout for Firmonertinib in 929 days (Oct 31, 2028), making the timing of OrbiMed's position particularly relevant.
Short interest stands at 21.3% of float with 13.2 days to cover, indicating significant bearish positioning against OrbiMed's long thesis.
About ArriVent BioPharma, Inc.
ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It also engages in the development and commercialization of targeted cancer therapies for non-small-cell lung cancer (NSCLC) and other solid tumors. The company develops Furmonertinib, an epidermal growth factor receptor mutant-selective tyrosine kinase inhibitor that is in phase 3 clinical trial for the treatment of NSCLC patients; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
Full company profile →Short Interest
21.3%
13.2 days to cover
OrbiMed Advisors AVBP Position History
Frequently Asked Questions
Does OrbiMed Advisors own AVBP?
Yes. As of Q4 2025, OrbiMed Advisors holds 3,027,328 shares of ArriVent BioPharma, Inc. (AVBP) valued at $60.9M. This data comes from their SEC 13F filing.
How many hedge funds own AVBP?
3 specialist biotech hedge funds currently hold AVBP, including Cormorant Asset Management, Perceptive Advisors. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did OrbiMed Advisors first buy AVBP?
OrbiMed Advisors's position in AVBP was first reported in Q1 2024. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is OrbiMed Advisors's AVBP position increasing or decreasing?
OrbiMed Advisors held their AVBP position unchanged in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
AVBPCompany Page →
All fund holders, insider trades, catalysts, and cash runway
OrbiMed AdvisorsPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →